Fernández Rodríguez, M. ConcepciónRodríguez-Sevilla, Juan JoséFernández-Ibarrondo, LierniSánchez González, BlancaGibert Fernandez, Joan, 1988-Bento, LeyreGarcía, Juan FernandoSancho, Juan ManuelDíez-Feijóo, RamónCamacho Díaz, LauraGarcía-Retortillo, MontserratGimeno Vázquez, EvaColomo Saperas, Luis AlbertoGutierrez, AntonioBellosillo Paricio, BeatrizSalar Silvestre, Antonio2022-05-232022-05-232022Fernández-Rodríguez C, Rodríguez-Sevilla JJ, Fernández-Ibarrondo L, Sánchez-González B, Gibert J, Bento L, et al. Worse outcome and distinct mutational pattern in follicular lymphoma with anti-HBc positivity. Blood Adv. 2022 Jan 11; 6(1): 82-6. DOI: 10.1182/bloodadvances.20210053162473-9529http://hdl.handle.net/10230/53193Epidemiological studies have demonstrated the association between hepatitis B virus (HBV) infection and B-cell non-Hodgkin lymphoma (NHL), mainly for diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL). We studied a cohort of 121 patients with FL for HBV infection status, clinical features, and gene mutational profile. Anti-HBc was detectable in 16 patients (13.2%), although all had undetectable HBV DNA. Anti-HBcore+ (anti-HBc+) cases presented with older age at diagnosis than anti-HBc- cases (68.1 vs 57.2 years; P = .007) and higher β2-microglobulin (56.3% vs 28.9%; P = .04). All patients included in the study fulfilled criteria for treatment and received therapy with rituximab or rituximab-containing chemotherapy. There were no episodes of HBV reactivation or HBV hepatitis during treatment and/or maintenance. Remarkably, anti-HBc+ patients had significantly lower 10-year progression-free survival (PFS; 12.9% vs 58.3%; P < .0001) and overall survival (OS; 22.0% vs 86.2%; P < .0001), that remained at multivariate analysis. Gene mutational profiling of all cases showed that anti-HBc+ cases had higher incidence of ARID1A mutations and absence of EP300 mutations, 2 key epigenetic regulators in FL. Overall, our study shows that FL patients with resolved HBV infection have a worse outcome independently of other well-known clinical risk factors and a distinct gene mutational profile.application/pdfengCopyright © 2022 by The American Society of Hematology. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), http://creativecommons.org/licenses/by-nc-nd/4.0/ permitting only noncommercial, nonderivative use with attribution. All other rights reserved.Hepatitis BLimfomesQuimioteràpia combinadainfo:eu-repo/semantics/articlehttp://dx.doi.org/10.1182/bloodadvances.2021005316info:eu-repo/semantics/openAccess